GlassScriptPhysician profile
Stephen H Bush
NPI 1083875710
$30,316.86
in general payments reported to CMS, 2019-2025
31 companies · $2,729 in 2025
The $2,729 reported for 2025 was more than what 82% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,351 · 2020: $511 · 2021: $898 · 2022: $1,538 · 2023: $6,347 · 2024: $16K · 2025: $2,729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,624 · Food and Beverage: $3,958 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,398 · Travel and Lodging: $2,167 · Education: $23.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,850.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,623.75 |
| Food and Beverage | $3,958.25 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,397.50 |
| Travel and Lodging | $2,166.70 |
| Education | $23.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $9,823.51 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $7,226.22 | 2019-2025 | Lynparza |
| Glaxosmithkline, LLC. | $3,543.14 | 2022-2025 | Jemperli, Zejula |
| Intuitive Surgical, INC. | $3,499.30 | 2020-2025 | Da Vinci Surgical System |
| Applied Medical Resources Corporation | $1,498.65 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $1,005.36 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Integra Lifesciences Corporation | $630.00 | 2023 | Integra |
| Ethicon US, LLC | $472.35 | 2020-2024 | Vistaseal, Harmonic |
| Tesaro, INC. | $430.93 | 2019 | |
| Pfizer INC. | $396.91 | 2023-2025 | |
| Abbvie INC. | $175.95 | 2020-2025 | |
| Seagen INC. | $173.21 | 2022-2023 | Tivdak |
| Gynesonics, INC. | $164.39 | 2023-2025 | Sonata Sonography-Guided Transcervical Fibroid Ablation System, Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Genentech, INC. | $150.00 | 2025 | Columvi |
| Pacira Pharmaceuticals Incorporated | $125.00 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $124.11 | 2023-2024 | Mychoice Cdx |
| Foundation Medicine, INC. | $122.75 | 2023 | |
| Lupin INC. | $111.85 | 2019 | |
| Myovant Sciences INC. | $111.71 | 2021 | |
| Dilon Technologies, INC. | $100.31 | 2024 | Hemoblast Bellows |
| Mallinckrodt Enterprises LLC | $83.31 | 2019 | |
| Astellas Pharma US INC | $77.71 | 2024 | Veozah |
| Sumitomo Pharma America, INC. | $60.56 | 2024-2025 | Myfembree |
| Conmed Corporation | $48.60 | 2023 | Airseal |
| Hologic Sales and Service, LLC | $38.16 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.16 | 2021 | |
| Fennec Pharmaceuticals, INC. | $24.12 | 2025 | Fyarro |
| Convatec INC. | $22.70 | 2019 | |
| Davol INC. | $18.09 | 2025 | Arista |
| Baxter Healthcare | $17.24 | 2024 | Perclot |
| Novartis Pharmaceuticals Corporation | $16.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Bush listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.